MedPath

Tagged News

Madras Diabetes Research Foundation Partners with Russia's Almazov Centre for AI-Driven Diabetes Research

AIPrecision Medicine
  • The Madras Diabetes Research Foundation (MDRF) has signed a strategic MoU with Russia's Almazov National Medical Research Centre to advance diabetes research through international collaboration.
  • The partnership will focus on developing new diagnostics and treatment strategies for diabetes, with particular emphasis on gestational diabetes mellitus (GDM).
  • Both institutions will explore artificial intelligence and precision medicine applications in diabetes care, marking a significant step toward technology-driven therapeutic approaches.
  • The collaboration includes joint research projects, academic exchanges, training programs, and shared publications between the Chennai-based foundation and the Saint Petersburg medical center.

Abbisko's FGFR4 Inhibitor Irpagratinib Receives China's Breakthrough Therapy Designation for Hepatocellular Carcinoma

Precision MedicineOncologyMonoclonal AntibodyTargeted Therapy
  • Abbisko Therapeutics' irpagratinib (ABSK011) has received Breakthrough Therapy Designation from China's NMPA for treating hepatocellular carcinoma, marking the first precision-targeted therapy using molecularly defined biomarkers for this indication.
  • The highly selective FGFR4 inhibitor targets FGF19 overexpression, which affects approximately 30% of HCC patients worldwide and is associated with significantly worse prognosis.
  • Clinical data from the 2024 ESMO GI Congress showed irpagratinib combined with atezolizumab achieved a 50% objective response rate in FGF19-positive HCC patients previously treated with immune checkpoint inhibitors.
  • The designation will expedite regulatory approval processes, potentially making irpagratinib the first globally approved FGFR4 inhibitor for HCC treatment.

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)

NCT05904886Active, Not RecruitingPhase 3
Hoffmann-La Roche
Posted 9/14/2023

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

NCT04524871RecruitingPhase 1
Hoffmann-La Roche
Posted 11/1/2020

Pfizer's BRAFTOVI Combination Therapy Halves Death Risk in BRAF-Mutant Metastatic Colorectal Cancer

Targeted TherapyPrecision MedicineOncology
  • Pfizer announced that its BRAFTOVI® combination regimen demonstrated a 50% reduction in death risk for patients with BRAF V600E-mutant metastatic colorectal cancer.
  • The targeted therapy represents a major advance in treating this specific genetic subtype of colorectal cancer.
  • This breakthrough could significantly improve survival outcomes for patients harboring the BRAF V600E mutation in metastatic disease.

Caris Life Sciences Files for $300 Million IPO to Advance AI-Powered Precision Oncology Platform

Precision MedicineAIOncology
  • Caris Life Sciences has filed for an initial public offering aiming to raise up to $300 million, with plans to list on Nasdaq under the ticker symbol "CAI".
  • The company has developed an AI-powered precision medicine platform for oncology, built on a massive dataset of over 6.5 million tests from 849,000 cases, generating measurements of more than 38 billion molecular markers.
  • Caris' commercial portfolio includes MI Profile, a tissue-based molecular profiling solution, and Caris Assure, a blood-based profiling solution launched in Q1 2024 for therapy selection.

Roche Partners with Broad Clinical Labs to Advance SBX Sequencing for Critically Ill Newborns

Precision Medicine
  • Roche and Broad Clinical Labs have formed a strategic collaboration to develop applications using Roche's next-generation Sequencing By Expansion (SBX) technology, initially focusing on whole genome sequencing for critically ill newborns.
  • The partnership aims to establish SBX technology as a routine component of clinical care in neonatal intensive care units (NICUs), enabling faster diagnosis of genetic disorders like cystic fibrosis and sickle cell disease.
  • Beyond neonatal applications, the collaboration will explore SBX technology for RNA sequencing, including bulk and single-cell approaches, to unlock novel molecular insights into disease mechanisms and potential therapeutic targets.

Ulefnersen Shows Unprecedented Recovery in Young Patients with Rare FUS-ALS

Rare DiseasePrecision MedicineNeurology
  • Columbia University researchers report that ulefnersen, an experimental drug, demonstrated remarkable efficacy in treating FUS-ALS, a rare genetic form of ALS affecting young people.
  • In a small case series of 12 patients, two showed exceptional responses, including one young woman who regained the ability to walk and breathe independently after treatment.
  • The therapy reduced neurofilament light, a biomarker of nerve damage, by up to 83% after six months, suggesting potential for not just slowing but reversing functional losses in early intervention.

Servier to Present Phase 3 Data on IDH-Mutated Cancer Therapies at ASCO 2025

Precision MedicineTargeted TherapyOncology
  • Servier will showcase its precision medicine research for IDH-mutated cancers at the 2025 ASCO Annual Meeting in Chicago, focusing on chondrosarcoma, cholangiocarcinoma, and myelodysplastic syndrome.
  • The company, which allocates over 65% of its R&D budget to oncology, will present updates on several Phase 3 programs aimed at developing new treatment options for patients with IDH-mutated cancers.
  • As a global leader in IDH-mutant targeted therapies, Servier's presentations will reinforce its commitment to advancing precision medicine through mutation identification and understanding cancer progression mechanisms.

Rigel Pharmaceuticals Unveils Promising Final Data from GAVRETO and REZLIDHIA Clinical Trials at ASCO and EHA 2025

OncologyTargeted TherapyPrecision Medicine
  • Final data from the Phase 1/2 ARROW study demonstrates GAVRETO's durable efficacy in RET fusion-positive NSCLC, with a 70.3% overall response rate and median overall survival of 44.3 months.
  • GAVRETO shows promising anti-tumor activity in various RET fusion-positive solid tumors beyond lung cancer, including a 100% response rate in pancreatic cancer patients.
  • REZLIDHIA data supports its potential clinical benefit when used in earlier treatment lines for relapsed/refractory AML patients and as maintenance therapy, with particularly strong outcomes in patients with fewer prior therapies.

RWJBarnabas Health and Rutgers Cancer Institute to Present 45 Groundbreaking Studies at ASCO 2025

OncologyPrecision MedicineMonoclonal Antibody
• Researchers from RWJBarnabas Health and Rutgers Cancer Institute will showcase 45 innovative cancer studies at the 2025 ASCO Annual Meeting, highlighting advances across multiple tumor types and treatment approaches.
• A notable multisite randomized trial demonstrated that problem-solving skills training significantly improved depression, anxiety, and quality of life in young adults newly diagnosed with cancer compared to standard care.
• New research revealed that patients living in both food and clinical trial deserts had 27% lower likelihood of breast cancer trial enrollment, highlighting how geographic and socioeconomic barriers impact cancer care access.

City of Hope to Present Groundbreaking Cancer Advances at 2025 ASCO Annual Meeting

Precision MedicineOncology
  • City of Hope researchers will showcase innovative cancer treatments at the 2025 ASCO Annual Meeting, including promising data on safely readministering trastuzumab-deruxtecan to breast cancer patients after lung complications.
  • A precision medicine study identified specific genomic biomarkers in kidney cancer patients that predict better outcomes with adjuvant atezolizumab, potentially enabling more personalized treatment approaches.
  • Novel combination therapy using checkpoint inhibitors Vilastobart and atezolizumab showed tumor shrinkage in colorectal cancer patients previously unresponsive to immunotherapy, representing a significant breakthrough.

Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

NCT04896697RecruitingPhase 1
Xilio Development, Inc.
Posted 9/13/2021

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy

NCT03024996TerminatedPhase 3
Hoffmann-La Roche
Posted 1/3/2017
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy